TOG Review (RCOG Journal)

MRCOG Part 2

Urogynaecology and Pelvic Floor Problems

The use of urethral bulking agents in the treatment of stress urinary incontinence

Key Statistics

  • 25% — UI prevalence, women ≥20y (n≈28,000)
  • 32% — Overall bulking agent complication rate
  • 12–35% — Bulkamid® patients needing reinjection

Don't-miss facts

  1. Bulking agents are NOT first-line SUI treatment (Cochrane 2017) – offer only after conservative management fails and after full counselling on alternatives

  2. Counsel that bulking agents are permanent materials, efficacy is inferior to other surgery, durability is poor, and repeat injection is often needed (12–35% for Bulkamid®)

  3. TVT beats Bulkamid® on both subjective (99% vs 85%) and objective (95% vs 66%) cure, but with more complications

  4. Overall complication rate 32% (mostly minor/transient); 3% major, needing further procedure

  5. Fatal PE reported after autologous fat migration – halted its use as a bulking agent

  6. National mesh pause since July 2018 – retropubic MUT remains an option but counsel as permanent implant with possible incomplete removal

  7. NICE 2019: local MDT for any invasive SUI procedure; regional MDT for repeat surgery, mesh complications, or future pregnancy plans

  8. Bulking agents are technically easier to learn → risk of widespread adoption ahead of long-term safety/efficacy data, echoing lessons from mesh

Agents at a glance

Current UK: Bulkamid® · Macroplastique® · Durasphere® · Coaptite® · Urolastic®

Withdrawn: bovine collagen (Contigen®, 2011) · autologous fat (fatal PE)

Abbreviation Key

  • UI — urinary incontinence
  • BMI — body mass index
  • SUI — stress urinary incontinence
  • MUT — mid-urethral tape
  • MUI — mixed urinary incontinence
  • TVT — tension-free vaginal tape
  • UUI — urgency urinary incontinence
  • MDT — multidisciplinary team
  • ISD — intrinsic sphincter deficiency
  • PROMS — patient reported outcome measures
  • NICE — National Institute for Health and Care Excellence
  • COPD — chronic obstructive pulmonary disease
  • PFMT — pelvic floor muscle training
  • IGF-1 — insulin-like growth factor 1

Source: McGowan S, Campbell P, Dolan L. The use of urethral bulking agents in the treatment of stress urinary incontinence. The Obstetrician & Gynaecologist 2020;22:137–146. doi:10.1111/tog.12647

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free